Journal of Clinical Pediatrics >
Clinical efficacy of nusinersen in treating presymptomatic 5q spinal muscular atrophy: a case report and literature review
Received date: 2021-11-05
Online published: 2022-03-09
To explore the clinical efficacy of nusinersen in treating presymptomatic 5q spinal muscular atrophy (SMA). The relevant clinical data, from a baby with presymptomatic 5q SMA were retrospectively collected, and a comprehensive analysis was made based on the existing literature. A 10-month-old girl got MLPA examination after birth because of the family history of SMA, and the results showed the homozygous deletions of SMN1 gene exon 7 and 8 and two copies of SMN2 gene. Physical examination showed that she had normal muscle strength and tone and good motor function, and therefore she was diagnosed with presymptomatic 5q SMA. Five doses of nusinersen have been treated by intrathecal injection according to the medication plan, and no adverse reactions have been observed. The milestones of motor development are basically normal. It is suggested that nusinersen treatment during the presymptomatic stage can achieve the best effect in children with 5q SMA, and the motor development milestone is expected to reach the normal level.
Key words： 5q spinal muscular atrophy; nusinersen; clinical efficacy
Zhiqiang LUO , Xinguo LU , Liqin LIU , Jianxiang LIAO . Clinical efficacy of nusinersen in treating presymptomatic 5q spinal muscular atrophy: a case report and literature review[J]. Journal of Clinical Pediatrics, 2022 , 40(3) : 208 -211 . DOI: 10.12372/jcp.2022.21e1539
| [1] | Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy[J]. N Engl J Med, 2018, 378(7): 625-635. |
| [2] | Arnold ES, Fischbeck KH. Spinal muscular atrophy[J]. Handb Clin Neurol, 2018, 148: 591-601. |
| [3] | Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study[J]. Lancet, 2016, 388(10063): 3017-3026. |
| [4] | Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy[J]. CNS Drugs, 2021, 35(12): 1317-1328. |
| [5] | Kolb SJ, Kissel JT. Spinal muscular atrophy[J]. Neurol Clin, 2015, 33(4): 831-846. |
| [6] | Ross LF, Kwon JM. Spinal muscular atrophy: past, present, and future[J]. Neoreviews, 2019, 20(8): e437-e451. |
| [7] | Serra-Juhe C, Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors[J]. Eur J Hum Genet, 2019, 27(12): 1774-1782. |
| [8] | 陈瑜毅, 韩蕴丽, 李杏, 等. 31例儿童脊髓性肌萎缩症临床与基因分析[J]. 临床儿科杂志, 2021, 39(10): 745-749. |
| [9] | Calucho M, Bernal S, Alías L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases[J]. Neuromuscul Disord, 2018, 28(3): 208-215. |
| [10] | Finkel RS, McDermott MP, Kaufmann P, et al. Obser-vational study of spinal muscular atrophy type I and implications for clinical trials[J]. Neurology, 2014, 83(9): 810-817. |
| [11] | Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model[J]. Genes Dev, 2010, 24(15): 1634-1644. |
| [12] | De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study[J]. Neuromuscul Disord, 2019, 29(11): 842-856. |
| [13] | Vill K, Kölbel H, Schwartz O, et al. One year of newborn screening for SMA - results of a German Pilot Project[J]. J Neuromuscul Dis, 2019, 6(4): 503-515. |
| [14] | Butterfield RJ. Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency[J]. Semin Pediatr Neurol, 2021, 38: 100899. |
| [15] | Albrechtsen SS, Born AP, Boesen MS. Nusinersen treatment of spinal muscular atrophy - a systematic review[J]. Dan Med J, 2020, 67(9): A02200100. |
| [16] | Jalali A, Rothwell E, Botkin JR, et al. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy[J]. J Pediatr, 2020, 227: 274-280. |
/
| 〈 |
|
〉 |
